Yearly Archives: 2025
Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
Canary Speech announces it has obtained HITRUST e1 Certification, reinforcing its commitment to cybersecurity related to its voice biomarker technology.
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval.
GE HealthCare’s Economic Impact Across Utah
GE HealthCare’s Economic Impact Across Utah
RefloDx Wins Trans Atlantic Angel Grand Prize
RefloDx Wins Trans Atlantic Angel Grand Prize.
Webinar Recap: Immigration Compliance Under Pressure
As immigration enforcement and workplace inspections intensify under the current administration, companies in the life sciences sector, particularly those with manufacturing operations, must be proactive in strengthening compliance. Presented by Ogletree Deakin’s Kathleen Weron on July 1, 2025, this webinar provided an overview of the essential components of I-9 compliance, strategies for responding to audits, […]
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES
2025 BIO International Recap
BioUtah and its Utah consortium made their mark this week at the BIO International Conference, hosting a Utah Pavillion to promote the state’s fast-growing life sciences industry. The conference, held in Boston, MA. drew appproximately 20,000 attendees. The Utah delegation included BioUtah, Utah life sciences companies, the Governor’s Office of Economic Development, the Unversity of […]
Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
Strategic Expansion in Salt Lake City Headquarters Will Meet Stringent EU GMP Annex 1 Requirements
RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS
